Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Immune targets and neoantigens for cancer immunotherapy and precision medicine

(2016) Rong-Fu Wang et al.   CELL RESEARCH

Autophagy proteins in antigen processing for presentation on MHC molecules

(2016) Christian Münz   IMMUNOLOGICAL REVIEWS

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+T Cells after Intercellular Antigen Transfer

(2015) Jean Francois Fonteneau et al.   JOURNAL OF IMMUNOLOGY

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

From virotherapy to oncolytic immunotherapy: where are we now?

(2015) Robert S Coffin   Current Opinion in Virology

Oncolytic immunotherapy: The new clinical outbreak

(2015) Jean-François Fonteneau et al.   OncoImmunology

Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

(2014) E. Galanis et al.   CANCER RESEARCH

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Measles Virus Vaccine-Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells

(2013) J.-B. Guillerme et al.   CLINICAL CANCER RESEARCH

Oncolytic viruses as therapeutic cancer vaccines

(2013) David L Bartlett et al.   Molecular Cancer

Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies

(2013) Samuel T Workenhe et al.   MOLECULAR THERAPY

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Fiji: an open-source platform for biological-image analysis

(2012) Johannes Schindelin et al.   NATURE METHODS

Measles virus causes immunogenic cell death in human melanoma

(2011) O G Donnelly et al.   GENE THERAPY

Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing

(2010) Fabrice Le Boeuf et al.   MOLECULAR THERAPY

A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers

(2010) Jean-Simon Diallo et al.   MOLECULAR THERAPY

Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response

(2008) A. Gauvrit et al.   CANCER RESEARCH

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

(2008) J Foloppe et al.   GENE THERAPY

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

(2008) Naomi N. Hunder et al.   NEW ENGLAND JOURNAL OF MEDICINE